Lalitha Nayak, MD
Hematology · Indianapolis, INNPI 1699803866
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $8,100 of the $11,199 with a category attached, or 72.3%. Alnylam Pharmaceuticals Inc. accounts for 83.9% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2019 at $9,817 and has fallen 95.7% since, to $426 in 2024.
Across 72 payments — averaging $155.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$9K
- Genentech USA, Inc.$514
- Novartis$199
- CSL Behring$112
- Sanofi$100
- Incyte Corporation$91
- plus $790 from 23 others
What the payments were for
- Consulting fees$8,10072%
- Travel & lodging$1,16910%
- Food & beverage$1,93017%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alnylam Pharmaceuticals Inc. | 7 | $9,393 |
| Genentech USA, Inc. | 7 | $514 |
| Novartis | 9 | $199 |
| CSL Behring | 1 | $112 |
| Sanofi | 4 | $100 |
| Incyte Corporation | 5 | $91 |
| AstraZeneca | 5 | $85 |
| Astellas Pharma US Inc | 3 | $77 |
| Amgen | 4 | $75 |
| Seagen Inc. | 3 | $48 |
| AVEO Pharmaceuticals, Inc. | 2 | $47 |
| Merck | 2 | $43 |
| Daiichi Sankyo Inc. | 1 | $41 |
| Beigene USA, Inc. | 2 | $38 |
| Agios Pharmaceuticals, Inc. | 1 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Bayer | 2 | $31 |
| Lilly USA, LLC | 1 | $25 |
| Morphosys, US Inc. | 1 | $24 |
| Helsinn Therapeutics (U.S.), Inc. | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Eisai Inc. | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Taiho Oncology, Inc. | 1 | $19 |
| Pfizer | 1 | $19 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| ADC Therapeutics America, Inc. | 1 | $19 |
| Dova Pharmaceuticals | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Indianato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tranexamic Acid | 16 | $3,980 |
| Deferasirox | 11 | $3,934 |
Paid to pharmacies, not to this prescriber.
Other hematology in Indianapolis
- Rafat AbonourIndianapolis$712K
- Luke AkardIndianapolis$358K
- Felix MensahIndianapolis$152K
- Brandon HardestyIndianapolis$72K
- Fatemeh Ardeshir LarijaniIndianapolis$3K
- Varun MittalIndianapolis$363
- Jennifer SchwartzIndianapolis$108
- Kenneth OforiIndianapolis$51
- Rakesh MehtaIndianapolis$13
- Sherif FaragKokomo$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.